Operating at the intersection of biotechnology and advanced healthcare, Orthocell Ltd continues to focus its strategic efforts on addressing significant unmet clinical needs within the global orthopaedics field. As a specialized biotechnological development company, the firm is dedicated to the advancement of biological therapies, specifically targeting the repair and regeneration of tendon and ligament tissues.
The company’s mission centers on providing innovative solutions for tissue regeneration, a critical area of medical science aimed at improving patient outcomes in orthopaedic recovery. By focusing on biological therapies, Orthocell Ltd seeks to move beyond traditional mechanical repairs, aiming instead to facilitate the body’s natural healing processes through sophisticated biotechnological applications.
From a market perspective, Orthocell Ltd is listed on the ASX All Markets exchange. As of the close of trading on November 16, 2026, the company’s shares were valued at 0.555 AUD, with a total market capitalization of 155,260,000 AUD.
The stock has experienced notable volatility over the past year. While the company reached a 52-week high of 1.16 AUD at the beginning of 2026, it saw a 52-week low of 0.49 AUD in late October 2026. Currently, the company maintains a price-to-earnings ratio of -10.57, reflecting its ongoing position as a development-stage biotechnology firm focused on long-term clinical advancements.




